Jiang Zhecheng, Wang Xianfeng, Yan Litao, Nan Hao, Chen Lingze, Gu Chencheng, Li Huan, Li Yun
Department of Articular Orthopaedics, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.
Department of Orthopedic Surgery, Beijing Jishuitan Hospital Guizhou Hospital Guiyang 550000, Guizhou, China.
Am J Transl Res. 2025 Aug 15;17(8):6019-6027. doi: 10.62347/ICOU1354. eCollection 2025.
To assess the effectiveness of arthroscopic debridement (AD) combined with Bupivacaine Liposome and 1,4-Butanediol Diglycidyl Ether (BDDE)-Crosslinked Sodium Hyaluronate in treating knee osteoarthritis (KOA).
A total of 195 KOA patients were recruited and assigned to two groups based on the treatment modality: a control group (n=95) receiving standard AD and a research group (n=100) receiving the combined therapy. The efficacy of the treatment, inflammatory biomarkers (including tumor necrosis factor-alpha [TNF-α], interleukin [IL]-1β, and IL-6), quality of life (QOL), and patient-reported satisfaction were assessed. Besides, multiple scales were employed, including the Visual Analog Scale (VAS) for pain intensity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for symptom severity, as well as the Hospital for Special Surgery (HSS) Knee Score and Lysholm Knee Score for functional recovery.
The research group demonstrated significantly superior overall efficacy and treatment satisfaction compared to the control group (P<0.05). Post-intervention improvements were observed in knee function scores (HSS and Lysholm) and QOL in both cohorts, with the research group showing greater enhancements (P<0.05). Furthermore, the combination therapy led to more pronounced reductions in WOMAC subscale scores (dysfunction, pain, and stiffness), VAS scores, and inflammatory markers (TNF-α, IL-1β, and IL-6) compared to the control group (P<0.05).
The combination of Bupivacaine Liposome, BDDE-Crosslinked Sodium Hyaluronate, and AD shows great therapeutic potential in the management of KOA, supporting its broad clinical generalization.
评估关节镜清创术（AD）联合布比卡因脂质体和1,4-丁二醇二缩水甘油醚（BDDE）交联透明质酸钠治疗膝骨关节炎（KOA）的有效性。
共招募195例KOA患者，根据治疗方式分为两组：对照组（n = 95）接受标准AD治疗，研究组（n = 100）接受联合治疗。评估治疗效果、炎症生物标志物（包括肿瘤坏死因子-α [TNF-α]、白细胞介素 [IL]-1β和IL-6）、生活质量（QOL）以及患者报告的满意度。此外，采用了多个量表，包括用于疼痛强度的视觉模拟量表（VAS）、用于症状严重程度的西安大略和麦克马斯特大学骨关节炎指数（WOMAC），以及用于功能恢复的特种外科医院（HSS）膝关节评分和Lysholm膝关节评分。
与对照组相比，研究组的总体疗效和治疗满意度显著更高（P<0.05）。两组患者干预后的膝关节功能评分（HSS和Lysholm）和QOL均有所改善，研究组改善更明显（P<0.05）。此外，与对照组相比，联合治疗导致WOMAC子量表评分（功能障碍、疼痛和僵硬）、VAS评分和炎症标志物（TNF-α、IL-1β和IL-6）的降低更为显著（P<0.05）。
布比卡因脂质体、BDDE交联透明质酸钠和AD联合应用在KOA治疗中显示出巨大的治疗潜力，支持其广泛的临床推广。
